中文

News Center

Dr. Yongliang Fang on Endpoints News：Chinese biotech unveils first-in-class tri-agonist for high lipids

2025/12/31

Read more

Doer Biologics Announces First Patient Dosed in Phase Ib Clinical Trial of DR30206 for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

2025/11/21

Read more

Doer Biologics' Globally First-in-Class Drug DR10624 Phase II Clinical Data Presented in Opening Session at AHA 2025

2025/11/11

Read more

Blockbuster | Up to 75% Reduction in Triglycerides, Up to 67% Reduction in Liver Fat: Doer Bio's DR10624 Phase 2 Clinical Results Shine in Opening Session at AHA 2025

2025/11/11

Read more

Preview | To Kick Off the Conference!Huadong Medicine’s Subsidiary Doer Bio's DR10624 Phase 2 Results for Severe Hypertriglyceridemia Selected as AHA 2025 Late-Breaker and Featured as Opening Presentation

2025/09/16

Read more

道尔生物完成DR10624治疗代谢相关脂肪性肝病（MASLD）/代谢相关脂肪性肝炎（MASH）的II期临床试验的首例患者给药

2025/04/22

Read more

Doer Biologics Announced Completes Enrollment of the Phase 2 Clinical Study of DR10624, reported by mainstream media

2025/03/12

Read more

道尔生物完成DR10624治疗重度高甘油三酯血症的2期临床研究的全部患者入组

2025/03/10

Read more

Doer Biologics Announced First Patient Dosed in Phase 2 Study of DR10624, reported by mainstream media

2024/10/09

Read more

全球首创3靶点激动剂DR10624用于肥胖合并高甘油三酯血症的1b/2a期临床试验完成全部受试者入组

2024/07/09

Read more